1.7. Analysis.
Comparison 1 RISPERIDONE vs PLACEBO, Outcome 7 Mental state: 2. skewed data ‐ short term (up to 12 weeks).
Mental state: 2. skewed data ‐ short term (up to 12 weeks) | ||||
---|---|---|---|---|
Study | Intervention | Mean | SD | N |
average endpoint score BPRS total (high=poor) | ||||
Pai 2002 | Resperidone | 14.7 | 7.4 | 22 |
Pai 2002 | Placebo | 19.0 | 12.2 | 20 |
average change score of CGI‐C (larger decline=good) | ||||
Potkin 2006 | Resperidone | 2.4 | 1.23 | 152 |
Potkin 2006 | Placebo | 2.9 | 0.84 | 71 |
average change score of CGI‐SI (larger decline=good) | ||||
Potkin 2006 | Resperidone | ‐1.84 | 1.23 | 152 |
Potkin 2006 | Placebo | ‐1.1 | 0.84 | 71 |
average change score of HAM‐D‐17 (larger decline=good) | ||||
Potkin 2006 | Resperidone | ‐5.6 | 4.93 | 152 |
Potkin 2006 | Placebo | ‐4.4 | 4.21 | 71 |
average change score of PANSS total (larger decline=good) | ||||
Potkin 2006 | Resperidone | ‐27.7 | 18.49 | 152 |
Potkin 2006 | Placebo | ‐20.2 | 16.85 | 71 |
average change score of PANSS negative symptom (larger decline=good) | ||||
Potkin 2006 | Resperidone | ‐4.0 | 4.93 | 152 |
Potkin 2006 | Placebo | ‐3.5 | 5.06 | 71 |
average change score of PANSS positive symptom (larger decline=good) | ||||
Potkin 2006 | Resperidone | ‐8.7 | 6.16 | 152 |
Potkin 2006 | Placebo | ‐5.3 | 5.9 | 71 |